While insurers and lawmakers assail prices for weight-loss treatments, Novo and Eli Lilly & Co. are striving to show their costly drugs offer broad benefits that merit coverage from insurers and government health plans.
The research highlights the relationship between obesity and Covid disease severity. We do not know if this relates to the reduced lung capacity of individuals with obesity or other pathways such as reduced inflammation.
The latest results underscore the drug's far-reaching effects on metabolism and inflammation, important factors in the body's response to infection and other types of disease.
It's not just weight loss, it's about the broad spectrum of health benefits that can improve quality of life and potentially reduce health risks.
Collection
[
|
...
]